Accium announces new pricing for AMS measurement service

Accium BioSciences, a leading provider of bioanalytical accelerator mass spectrometry (AMS) services in North America, announced today new pricing for its AMS measurement service at $99 per sample. GLP-compliant service is now available at $115 per sample. The new pricing includes sample graphitization and AMS measurement services. Accium will continue to provide expert bioanalytical and quality assurance services at competitive rates.

"This new pricing is designed to reach a broader research market and is the result of Accium's expanded capacity and steadfast focus on operational efficiencies," said Ali Arjomand, Ph.D., Accium's President and Chief Operating Officer.

Concurrent with this announcement, Accium is launching the DirectAMS™ Program, a streamlined service for customers who only seek graphitization and AMS services. For the first time, such customers may submit samples directly to the AMS Services Unit, bypassing Accium's bioanalytical service offerings. The fee for this service is also $99 (non-GLP) and $115 (GLP) and includes standard reporting of results. As an optional add-on to this program, Accium is providing an enabling service to anyone who seeks to establish their own independent bioanalytical laboratory. The $12,500 annual subscription package includes Accium's up-to-date SOP library, 12 hours of consulting and Accium's Monitoring Kit that includes 40 AMS measurements. The academic/non-profit rate is $7,500 per year and includes six hours of consulting, Accium's SOP library and 40 AMS measurements. This subscription program is ideally suited for academic groups and contract research organizations who can now gain seamless access to quality AMS service at $99/$115 per sample. The fees announced today apply to all samples and study types with the exception of absolute bioavailability (IV microtracer) studies performed at Accium.

"We are well positioned to work with new market segments to apply the power of Accium's AMS-based services in ways that will positively impact research and drive new innovations across the healthcare spectrum," stated Dr. Glenn Kawasaki, Accium's Chief Executive Officer.